Arrowhead Pharmaceuticals Appoints Dr. Matt Cohen to Board of Directors

On June 12, 2026, Arrowhead Pharmaceuticals, Inc. appointed Dr. Matt Cohen, M.D., M.B.A., to its Board of Directors, effective immediately. Dr. Cohen brings over 25 years of extensive experience in healthcare investing and portfolio management. He currently serves as Managing Director at Vida Ventures and previously spent two decades at JP Morgan Asset Management, where he was the lead portfolio manager for the flagship JP Morgan Global Healthcare Fund and oversaw multi-billion-dollar growth healthcare assets. As part of his appointment, Dr. Cohen will receive the company's standard compensation for non-employee directors, including a sign-on grant of restricted stock units (RSUs) valued at $887,000. These RSUs are scheduled to vest over a three-year period. There are no reported family relationships or arrangements between Dr. Cohen and any other company executives or directors that influenced his appointment. This addition strengthens the board's expertise in healthcare investment strategy and fundamental analysis.